Logotipo de Valence
populares
Iniciar sesión
Loading data for ERAS — first visit, this takes a few seconds.

Añadir a la lista de seguimiento

Erasca Inc.

NasdaqGS: ERAS · Precio en tiempo real · USD
18.10
-0.18 (-0.98%)
Al cierre: Aug 18, 2026, 8:00 PM
18.10
+0.00%
Premercado: 5:48 AM

Erasca Inc. (ERAS) Stock Price, Analysis & Data

-0.98%

No hay datos disponibles

Precio de compra13.27
Capitalización de mercado6.33B
Ingresos (TTM)n/a
Beneficio neto (TTM)-287.22M
Beta0.65
EPS (TTM)-0.95
Ratio PER (TTM)n/a
Adelante PE-31.11
P/B (TTM)15.63
P/S (TTM)n/a
Earnings DateNov 11, 2026
Precio de venta23
Volumen1,830,092
Volumen medio (20D)4,923,824
Abierto18.19
Anterior Cerrar18.28
Rango del día17.85 - 18.72
Rango de 52 semanas1.33 - 24.28
analistan/a
Precio objetivon/a
Dividendosn/a
Fecha ex dividendon/a

Acerca de ERAS

Erasca, Inc., a clinical-stage precision oncology company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's product pipeline includes ERAS-0015, a pan-RAS molecular glue for the treatment of patients with RAS-mutated solid tumors; ERAS-4001, a pan-KRAS inhibitor for the treatment of patients with KRAS-mutated solid tumors; and ERAS-12, an investigational EGFR D2/D3 ...

[Leer más]
Industria Biotechnology
Sector Healthcare
IPO Fecha Jul 16, 2021
Empleados 103
Bolsa de Valores NasdaqGS
Símbolo bursátil ERAS
Sitio web https://www.erasca.com
Perfil completo de la empresa

Desempeño financiero

En 2025, los ingresos de Erasca fueron 0, un aumento de undefined% en comparación con 0 del año anterior. Las ganancias fueron -124.55M, una disminución de -22.95%.

Estados financieros

Sorpresa de resultados

Erasca ha publicado sus resultados trimestrales en Aug 11, 2026:
  • Ingresos de $0 falla las estimaciones por $0, con NaN% Crecimiento interanual.
  • EPS de -0.14 falla las estimaciones por -0.03, con -16.67% Disminución interanual.

    • Próxima publicación de resultados

    Está previsto que Erasca Inc. publique sus resultados el Nov 11, 2026, durante el horario de mercado.
    Los analistas proyectan ingresos de ... Actualizar
    news image

    1 mes hace · Simply Wall St.

    Erasca (ERAS) Stock Looks Overvalued On Price But Strong On Returns

    Erasca stock has delivered an extremely large 1 year gain, yet its valuation checks lean expensive, so the current price is testing how much optimism investors are willing to embed into the story this...

    news image

    1 mes hace · Simply Wall St.

    Erasca (ERAS) Trial Update Draws Fresh Focus, Is The Valuation Already Full?

    Erasca (ERAS) has been in focus after updated preliminary Phase 1 data for ERAS-0015 in RAS-mutant solid tumors, including pancreatic cancer, coincided with a sizeable follow-on equity offering and a ...

    news image

    1 mes hace · Simply Wall St.

    Erasca (ERAS) Is Up 6.2% After Advancing ERAS-0015 Toward Registration Trials In RAS Cancers

    Erasca recently reported updated preliminary Phase 1 data for its oral pan-RAS molecular glue ERAS-0015, showing encouraging responses and a generally well-tolerated safety profile in RAS-mutant solid...

    news image

    1 mes hace · Insider Monkey

    Erasca (ERAS) Surges 8.9% on Encouraging Cancer Trial Results

    Erasca rallied by 8.94 percent on Tuesday to close at $19.50 apiece, as investor sentiment was boosted by the strong clinical trial results of its treatment candidate for RAS-mutant solid tumors, stre...

    news image

    1 mes hace · Barrons.com

    Robinhood and 4 More Stocks That Were Just Added to This Firm’s ‘Top Picks’ List

    Robinhood Markets is added as a top stock for July. Micron and Oracle are among Mizuho Securities’ top picks for the month.

    Página 1 de 2